- Ajinomoto’s 1st quarter net sales reached 365.51 billion yen, beating the estimate of 361.67 billion yen by 7.7% year-over-year.
- Net income for the 1st quarter was 23.97 billion yen, showing a 12% decline year-over-year and falling short of the estimate of 28.29 billion yen.
- For the year 2025, Ajinomoto maintains its forecast for net sales at 1.53 trillion yen, while the estimate is 1.54 trillion yen.
- The company also sticks to its net income forecast for 2025 at 95.00 billion yen, which is lower than the estimate of 101.37 billion yen.
- Ajinomoto’s projected dividend for 2025 remains at 80.00 yen, slightly below the estimate of 82.73 yen.
- The current analyst recommendations for Ajinomoto are: 8 buys, 7 holds, and 1 sell.
- Comparisons to past results are based on the company’s original disclosures.
A look at Ajinomoto Co Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 2 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts utilizing the Smartkarma Smart Scores have given Ajinomoto Co a positive long-term outlook based on its scores in various key factors. The company scores well in areas such as Growth with a score of 4 and Momentum with a top score of 5. This indicates a strong potential for Ajinomoto Co to expand its business and maintain an upward trend in the future.
Ajinomoto Co, known for its production and sale of food products, pharmaceuticals, amino acids, and specialty chemicals, demonstrates the potential for sustained growth and market resilience. Although some areas like Value and Dividend show room for improvement with scores of 2, the overall outlook for Ajinomoto Co remains promising based on the Smartkarma Smart Scores.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
